Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma

Molecular Targeted Therapy of Biliary Tract Cancer – Results of the First Clinical Studies

(2010) Marcus W. Wiedmann et al.   CURRENT DRUG TARGETS

Long-Term Administration of Wilms Tumor-1 Peptide Vaccine in Combination with Gemcitabine Causes Severe Local Skin Inflammation at Injection Sites

(2010) A. Soeda et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study

(2010) Sam J. Lubner et al.   JOURNAL OF CLINICAL ONCOLOGY

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preliminary Experience of Cetuximab in the Treatment of Advanced-Stage Biliary Tract Cancer

(2010) Ping-Ying Chang et al.   ONKOLOGIE

Gemcitabine, irinotecan and celecoxib in patients with biliary cancer

(2009) James F. Watkins et al.   ANTI-CANCER DRUGS

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study

(2009) J W Valle et al.   BRITISH JOURNAL OF CANCER

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

(2009) C Bengala et al.   BRITISH JOURNAL OF CANCER

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

(2009) Ramesh K. Ramanathan et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Alternate Endpoints for Screening Phase II Studies

(2009) N. Dhani et al.   CLINICAL CANCER RESEARCH

American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study

(2009) Andrew X Zhu et al.   LANCET ONCOLOGY

Capecitabine and Celecoxib as Second-Line Treatment of Advanced Pancreatic and Biliary Tract Cancers

(2009) Maria S. Pino et al.   ONCOLOGY

Chemoradioimmunotherapy in Locally Advanced Pancreatic and Biliary Tree Adenocarcinoma

(2009) Francesco Recchia et al.   PANCREAS

Safety of an Immunosuppressant Protocol Based on Sirolimus in Liver Transplant Recipients With Malignancies or High Risk of Tumor Recurrence

(2009) J.F. Castroagudín et al.   TRANSPLANTATION PROCEEDINGS

Lapatinib/Gemcitabine and Lapatinib/Gemcitabine/Oxaliplatin

(2008) Howard Safran et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Optimising the design of phase II oncology trials: The importance of randomisation

(2008) Mark J. Ratain et al.   EUROPEAN JOURNAL OF CANCER

Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

(2008) Magnus Rizell et al.   International Journal of Clinical Oncology

A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors

(2008) E. T. Lam et al.   MOLECULAR CANCER THERAPEUTICS

Systemic Therapy for Biliary Tract Cancers

(2008) A. F. Hezel et al.   ONCOLOGIST